The burgeoning field of complementary medicines, including weight-loss products, is now a billion-dollar industry. Every year, more people are spending disposable income on complementary and alternative medicines that may prove to have no benefit for our health.
Garcinia Cambogia is one such example. Marketed as a weight-loss pill, it has had an exponential rise in sales since it was featured on the Doctor Oz show.
Garcinia cambogia is the former scientific name of a native Southeast Asian plant, belonging to the family Clusiaceae, that bears a pumpkin-shaped fruit. The skin of the fruit contains the active ingredient, hydroxycitric acid (HCA). HCA inhibits an enzyme that produces fatty acid, thus suppressing fatty acid and the processing of cholesterol.
But does this mode of action translate to the weight-loss claims associated with it? Or is it just clever marketing convincing us this product helps us lose weight?
An Australian advertisement for the weight-loss supplement Garcinia Cambogia. Screenshot, http://www.garciniacambogiasave.com/, CC BY
Double-blinded, randomised controlled trials are the gold standard of clinical study and whenever possible should be conducted to test the effectiveness of a treatment compared to a placebo. Weight-loss products should be assessed for a minimum of six months, with a further six-month follow-up period (12 months total).
There has never been a long-term study investigating the efficacy of Garcinia Cambogia. Most of the studies have been conducted in animals.
In fact, the majority of well-designed trials investigating the effect of this product on weight loss have found no effect that is of clinical relevance. In a 12-week double-blind, placebo-controlled trial conducted in humans, people receiving 3000mg of Garcinia Cambogia extract (1500mg of the active component HCA) per day lost the same amount of weight as the control group.
Another 12-week study with a four-week follow-up (16 weeks total) also found no greater weight-loss effect than for a placebo control group. For those studies where a statistically significant effect was reported, the weight loss was around one kilogram more than for those receiving a placebo pill.
Positive and greater weight losses were found in some studies, but this effect is suppressed when looking at all of the studies combined.
The Garcinia Cambogia plant Livia Lacolare/Flickr, CC BY
With respect to other health benefits from taking this supplement, the evidence to suggest it can improve blood cholesterol levels is lacking.
Most importantly, the product safety profile of Garcinia Cambogia has been adequately tested and there appear to be no issues.
Some complementary medicines have been found to contribute to improved health outcomes, through increased efficacy and cost-effectiveness. However, if there is to be a role for such complementary and alternative weight-loss products and medicines, we must build upon the evidence to investigate whether these increasingly popular products are a viable treatment option.
A recent Obesity Australia and Price Waterhouse Coopers report found obesity cost Australia A$8.6 billion in 2011-2012, with the indirect costs far higher. We must establish whether complementary medicines have a role to play in preventing and treating obesity. If we take no action to reduce obesity rates, an additional 2.4 million people will become obese at a cost of $87.7 billion over 10 years.
Dr Nicholas Fuller has received research grants for other clinical trials funded by Australian Egg Corporation, Weight Watchers International, SOHO Flordis International, Arnotts Biscuits, Sanofi-Aventis, Novo Nordisk, Allergan, Roche products, MSD, and GlaxoSmithKline.
Nick Fuller, Research Fellow, Clinical Trials Development and Assessment, University of Sydney
This article was originally published on The Conversation. Read the original article.



Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 





